Recent studies underscore the importance of crosstalk between tumor-associated macrophages (TAMs) and tumor cells in cancer progression and metastasis. In our study, AdCD68STAT3β, a recombinant adenovirus containing a STAT3β gene driven by CD68 macrophage-specific promoter, was used to suppress STAT3 and the downstream signaling pathways in TAMs. The results showed that STAT3β gene under the control of CD68 macrophage-specific promoter was only expressed in macrophages, which significantly inhibited the motility and invasion of breast cancer cells when co-cultured with 4T1 cells. Moreover, cell-specific STAT3β expression in TAMs extended survival of tumor-bearing mice and suppressed breast tumor growth, angiogenesis and metastasis, by regulating the crosstalk between tumor cells and TAMs. Therefore, our study provided a novel strategy for the antitumor effects of STAT3β.
INTRODUCTION
The tumor microenvironment (TME) comprises a variety of nonmalignant stromal cells that have a pivotal role in tumor progression and metastasis. 1,2 TME is the cellular environment, including surrounding blood vessels, immune cells, fibroblasts, signaling molecules and the extracellular matrix. 3 Tumor-associated macrophages (TAMs) are the blood monocytes recruited into tumors by chemotactic cytokines and growth factors, such as C-C chemokine ligand 2 (monocyte chemotactic protein 1), macrophage colony-stimulating factor (colony-stimulating factor 1), vascular endothelial growth factor (VEGF), angiopoietin-2 and C-X-C chemokine ligand 12 (stomal cell-derived factor 1), which are released by both malignant and stromal tumor compartments. 4, 5 TAMs have an important role in the processes of tumor growth, angiogenesis, invasion and/or metastasis and immune-suppression. 5, 6 Accumulating evidence from clinical and epidemiological studies has suggested a strong association between TAM density and poor prognosis in several types of cancer. [7] [8] [9] [10] However, the underlying molecular mechanisms still remain unknown.
Through analyzing the crosstalk between TME and TAMs and TAMs and tumor cells, it has been found that signal transducer and activator of transcription 3 (STAT3), a signaling molecule, has a significant role. In a variety of tumor cells, STAT3 acts as a crucial oncogenic mediator and a potent transcriptional factor. [11] [12] [13] Constitutive activation of STAT3 in TAMs could promote tumor immunosuppression, angiogenesis, growth and metastasis. [13] [14] [15] Furthermore, STAT3 inhibition by overexpressing the STAT3 dominant-negative protein in tumors can induce a potent 'bystander' effect, killing tumor cells. 16 Therefore, STAT3 is considered to be an important target molecule for anticancer therapy.
STAT3β is a STAT3 splice variant and lacks the 55-residue C-terminal transactivation domain, which is replaced by seven unique amino acids. STAT3β can be efficiently phosphorylated at the key tyrosine 705 (Y705) with a lack of serine 727 (S727) binding to DNA elements as a homodimer or heterodimer (with STAT3α or other transcription factors). Therefore, STAT3β has been initially described as a dominant-negative factor and shown to inhibit gene transactivation, presumably by competitive promoter occupancy. It has been shown that STAT3β overexpression induces apoptosis and inhibits tumor growth. [16] [17] [18] [19] Macrophage-specific promoters can be used for gene delivery approaches as valuable tools to mediate STAT3β high expression in macrophages. Several different macrophage-specific promoters have previously been used and reported for gene deliveries. [20] [21] [22] It has been demonstrated that the CD68 gene promoter results in the highest levels of transgene expression, specifically in macrophages. 21 In this study, we delivered the STAT3β gene under the control of macrophage-specific promoter (CD68 promoter) into macrophage cells by adenoviral vectors and showed that STAT3β gene was specifically expressed in macrophage cells. Our data suggested that overexpression of STAT3β within macrophages could be a promising and more effective approach against breast tumor.
MATERIALS AND METHODS
Cell culture 4T1 cells, a murine breast tumor cell line derived from BALB/c mice, were provided kindly by Dr Rong Xiang, School of Medicine, Nankai University (Tianjin, China). Murine macrophage cells (RAW264.7), mouse mesenchymal stem cells (C3H10), human embryonic kidney cells (293) and murine melanoma cells (B16) were some gifts from Dr Yangan Wen. These cell lines were sourced from American Type Culture Collection (ATCC, Rockville, MD, USA). These cell lines were maintained in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal bovine serum (Gibco, Gaithersburg, MD, USA) at 37 ℃ with 5% CO 2 .
Recombinant adenovirus vectors
The adenovirus AdEasy system was a generous gift from Dr Tong-Chuan He (Molecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL, USA). To generate macrophagespecific gene expression vectors, CD68 gene promoter was amplified from pCD68. CD68 gene promoter was then inserted to BshI/XhoI site in pEGFP-N1 to replace cytomegalovirus (CMV) promoter, generating a new plasmid pCD68GFP. STAT3β cDNA was amplified from pSTAT3β and subcloned into HindIII and SmaI site of pCD68GFP, generating expression vector pCD68STAT3β. STAT3β gene along with macrophage-specific CD68 gene promoter was amplified from plasmid pCD68STAT3β and subcloned into EcoRV and SalI site of adenoviral vector pAdTrack-polyA, generating the recombinant shuttle vector pAdTrack-polyA-CD68STAT3β. For the primers used, see Table 1 . The adenoviruses were prepared as described previously. 23 Recombinant adenoviral vector encoding STAT3β under the control of CD68 gene promoter was designated as AdCD68STAT3β, and the control adenovirus with a dearth of the STAT3β gene was designated as Ad-C.
Establishment of orthotopic breast tumor model
The care of laboratory animal and the animal experimental operation were performed in strict accordance with Chongqing Management Approach of Laboratory Animal (Chongqing government order No. 195). The animal experiments were approved by the Ethics Committee of Chongqing Medical University (Reference number: CQMU 2010-26). Female BALB/c mice (5-7-week old) were purchased from the Experimental Animal Center of Chongqing Medical University (Chongqing, China) and acclimated to the laboratory conditions for 1 week before tumor implantation. A total of 2 × 10 6 4T1 cells suspended in 100 μl of phosphate-buffered solution (PBS) were injected into the fourth right mammary fat pad of the mice. Gross tumors were formed 2 weeks after tumor cell implantation.
Administration of AdCD68STAT3β to tumor-bearing mice
Thirty tumor-bearing mice were randomly divided into three groups (each 10 mice per experimental group): PBS group, Ad-C group, and AdCD68STAT3β group. In the PBS group, PBS was injected into tumor every 2 days for a total of three times. In the Ad-C and AdCD68STAT3β groups, 1 × 10 11 plaque-forming units of Ad-C or AdCD68STAT3β were Table 1 . Primers used in this study directly injected into tumors every 2 days for a total of three times, respectively. Tumor growth was evaluated by measuring tumor volume (TV = length × width 2 × 0.5) every 3 days until they were killed 2 weeks after treatment. Tumor allografts and the lungs of the mice were harvested for further evaluation. Immunofluorescent staining was performed with 4T1 tumor tissues. Rat anti-mouse F4/80 mAb (ABD Serotec, MorphoSys UK Ltd., Oxford, UK) were used as macrophage markers. TUNEL (terminal deoxinucleotidyl transferase-mediated dUTP-fluorescein nick end labeling), Ki-67 and CD31 immunohistochemical staining of tumor tissue sections was performed according to the manufacturer's protocol. Hematoxylin and eosin staining of lung tissue sections was used to indicate pulmonary metastasis in mouse models. Another batch of mice grouped as above was observed for survival until 60 days after tumor cell injection. Mortality was recorded for all animals.
Matrigel invasion assay
Matrigel invasion chamber in 24-well plates with 8-μm porous membranes were used. Matrigel were purchased from Becton Dickinson (Rockville, MD, USA). Pro-treated RAW264.7 cells were cultured in the bottom chamber as chemoattractant; 4T1 cells (1 × 10 4 ) were resuspended in serum-free media and seeded on top of the matrix. After incubation for 8 h, cells that had migrated through the matrix and the membrane were stained with 0.1% crystal violet and were counted as cells per field of view under phasecontrast microscopy.
In vitro scratch assay 4T1 cells were grown until the cells reached to 90% confluence. A linear wound was created in the confluent monolayer using a pipette tip. After incubation for 24 h, 4T1 cells were photographed under phase-contrast microscopy. Inhibition of cell motility was assessed by using the ImageJ software (National Institutes of Health, Bethesda, MD, USA). The percentage of wound healed was calculated using the formula: 100 − ((final area/initial area) × 100%).
Western blotting
Proteins extracted from cancer cells or macrophages were separated in sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel and transferred to polyvinylidene difluoride membrane, which were then probed with antibodies against pSTAT3β (Tyr 705) (1:2000, 4113; Cell Signaling Technologies, Beverly, MA, USA), STAT3 (1:2000, 610189; BD, San Jose, CA, USA), matrix metalloproteinase-9 (MMP-9; 1:1000, 2270; Cell Signaling Technologies), MMP-2 (1:1000, BS1236; Bioworld, Minneapolis, MN, USA), tissue inhibitors of metalloproteinase-1 (TIMP-1; 1:1000, BS1697; Bioworld), TIMP-2 (1:1000, BS1366; Bioworld), VEGF (1:1000, sc-7269; Santa Cruz Biotechnology, Santa Cruz, CA, USA) or β-actin (1:1000, sc-4778; Santa Cruz Biotechnology). Protein signals were visualized using enhanced chemiluminescence detection system (VIAGENE, Tampa, FL, USA).
Statistical analysis
Data were expressed as mean ± s.d. and analyzed using the Graph Pad Prism software (GraphPad Software Inc., La Jolla, CA, USA). Statistic significance was assigned at Po 0.05 (*/#), Po 0.01 (**/##) or Po0.001 (***/###). All experiments were performed at least three times with triplicate samples.
RESULTS
Macrophages-specific expression of STAT3β gene under the control of CD68 gene promoter CD68 gene promoter was amplified by PCR and inserted into pEGFP-N1 to generate pCD68GFP construct, which was transiently transfected into mouse peritoneal macrophages, murine macrophage RAW264.7 cells line and several non-macrophage cells. Cells were transfected with pEGFP-N1 and pCD68GFP, in which green fluorescent protein (GFP) was driven by CMV and CD68 promoters, respectively. Thirty-six hours after transfection, the transfected cells were observed under a fluorescence microscope and analyzed with flow cytometry. The results showed that GFP fluorescence was observed in all of the cells transfected with pEGFP-N1. In the cells transfected with pCD68GFP, the GFP fluorescence was only observed in macrophage cells (Figure 1a ). The results indicated that CD68 gene promoter directed macrophage-specific gene expression.
To further confirm whether CD68 gene promoter directed STAT3β gene expression in macrophage, CD68 gene promoter was placed upstream of STAT3β gene (Figure 1b ). RAW264.7 cells were treated with PBS, Ad-C or AdCD68STAT3β, and STAT3β gene expression was examined by reverse transcriptase-PCR and western blotting. As shown in Figure 1c , STAT3β gene expression with the PCR product of 158 bp was only detected in cells infected with AdCD68STAT3β. Furthermore, western blotting assay showed that STAT3β protein was predominantly expressed in RAW264.7 cells infected with AdCD68STAT3β (Figure 1d) . Therefore, the results demonstrated that STAT3β gene controlled by CD68 gene promoter was specifically expressed in macrophages.
STAT3β overexpression in macrophages affected 4T1 cell motility and invasion
To further explore whether STAT3β-overexpressing RAW264.7 cells would affect motility and invasion of tumor cells, we co-cultured 4T1 cells and RAW264.7 treated with PBS, Ad-C or AdCD68STAT3β. The ratio of 4T1 and RAW264.7cells was 2:1. In vitro scratch assay was conducted to evaluate the effect of macrophages on cancer cells. 4T1 cells were plated in the lower wells of Boyden chamber and macrophages in the upper chambers. After 24 h of co-culture, cancer cells exposed to AdCD68STAT3β-treated RAW264.7 cells moved more slowly to close the scratched wounds compared with those exposed to PBS or Ad-C-treated RAW264.7 cells (P o0.01, Figure 3 . Effects of AdCD68STAT3β on survival and tumor growth of tumor-bearing mouse. (a) Scheme depicting the experimental approaches. 4T1 cells were inoculated into the mammary fat pads of 6-week-old BALB/c mice. When tumor volume reached approximately 250 mm 3 , mice were injected PBS, Ad-C or AdCD68STAT3β every 2 days for a total of three times. Mice were killed on day 28, and tumors were harvested for further experiments. (b) Tumor volumes after treatment with PBS, Ad-C or AdCD68STAT3β. (c) The difference in tumor sizes at day 28 after three doses of treatment. (d) Immunofluorescent staining of tumor tissues. Virus were green (GFP), and macrophage marker F4/80 were red (anti-F4/80 antibody). DAPI (blue) was used to visualize cell nuclei. Graphical analysis of fraction of GFP+ cells in F4/80+ cells (TAMs) showed that 470% of F4/80+ cells were also GFP+ (n = 5, mean ± s.e.m.). Scale bar, 200 μm. (e) The difference of survival between AdCD68STAT3β treatment and control groups. Figure 2a ). Moreover, AdCD68STAT3β-treated RAW264.7 cells significantly reduced 4T1 cells invasion through matrigel (P o 0.001, Figure 2b ). Furthermore, we examined the expression levels of p-STAT3, MMP2, MMP9, TIMP-2, TIMP-1 and VEGF genes, which were related to the motility and invasion of tumor cells. The results showed that the expression of p-STAT3, MMP9, MMP2 and VEGF genes were decreased, while the expression of TIMP-2 and TIMP-1 genes were increased compared with the control groups (Figure 2c ).
Effects of AdCD68STAT3β on survival of tumor-bearing mice and tumor growth
To examine the effects of AdCD68STAT3β on tumor growth in vivo, 4T1 cells were inoculated into the mammary fat pads of 6-week-old BALB/c mice. When tumor volume reached approximately 250 mm 3 , PBS, Ad-C or AdCD68STAT3β were directly injected into the tumors, every 2 days for a total of three times. Then the effects of treatment on tumor growth were analyzed (Figure 3a ). As shown in Figure 3b , tumor sizes in the AdCD68STAT3β-treated group were significantly smaller than that of the control groups, and there was no difference in tumor volume between the PBS and Ad-C groups. On day 28, the mice were killed, and primary tumors were surgically excised. AdCD68STAT3β treatment resulted in a significant decrease in tumor weight, compared with the control groups (Figure 3c ).
To verify viral infection of TAMs, virus (GFP green) and macrophage marker F4/80 (red) in tumor tissues were examined by immunofluorescence. It was shown that virus infected preferentially F4/80+ macrophages (Figure 3d ). In addition, the survival curve showed that 80% (4/5) of the mice in the AdCD68STAT3β group remained tumor free for up to 2 months, whereas all control mice died within 42 days (Figure 3e ).
Effects of AdCD68STAT3β on tumor cell proliferation, apoptosis, angiogenesis and pulmonary metastasis in vivo
The proliferation of cancer cells, apoptosis, angiogenesis and pulmonary metastasis were investigated in vivo. In Figures 4a and 
DISCUSSION
STAT3 has been demonstrated to activate the genes related to angiogenesis, cell survival, immunnosuppression and invasion of diverse tumors, including malignant breast cancer. In our study, STAT3β gene was overexpressed to suppress STAT3 signaling pathways in TAMs, and the effects on suppression on tumor progression were investigated in vitro and in vivo. A recombinant adenoviral vector, AdCD68STAT3β, containing STAT3β gene driven by CD68 promoter, was used to overexpress STAT3β gene in macrophages. CD68 promoter was shown to result in macrophage-directed gene expression. The results showed that macrophages treated with AdCD68STAT3β significantly inhibited the motility and invasion of 4T1 cells in vitro and suppress breast tumor growth, angiogenesis and metastasis in vivo. Therefore, our data suggested that STAT3β under the control CD68 gene promoter can significantly and specifically inhibit STAT3 signaling pathway in TAMs, probably by regulating the crosstalk between tumor cells and TAMs.
Several lines of evidence indicate mutual relationship between cancer cells and TAMs in the TME. Cancer cells secrete chemokines to attract and enter macrophages. TAMs respond to tumor-derived molecules by producing extracellular matrix enzymes and growth factors, which, in turn, stimulate tumor proliferation, angiogenesis and metastasis. 24 Thus it is suggested that attenuation of TAMs in the tumor environment may be an effective way to remodel the TME.
STAT3, a point of convergence for numerous oncogenic signaling pathways, is constitutively activated in tumor cells and most of all stroma cells in the TME, including TAMs. 13 Currently, genetic approaches have been used to inhibit STAT3 in the myeloid compartment and B cells to circumvent the immunosuppressive tumor milieu that interferes with the functions of transferred T cells. 25 These studies have demonstrated the ability of STAT3 in regulating numerous genes crucial for premetastatic niche formation in bone marrow-derived cells. 26 STAT3 has two main isoforms, full-length STAT3α and truncated STAT3β, generated by alternative splicing of exon 23. STAT3β is an efficient dominant-negative regulator of STAT3-mediated transcription. 19 It is found that the overexpression of STAT3β leads to cell apoptosis and cell cycle arrest of murine melanoma B16 cells. 16 Furthermore, STAT3β, as a potent antitumorigenic molecule, can act as a dominant-negative regulator of transcription and promote apoptosis. 18 Inhibition of the STAT3 signaling pathway using a dominant-negative STAT3 (STAT3β) significantly suppresses the growth of ovarian and breast cancer cell lines harboring constitutively active STAT3. 27 Therefore, tissue-and organ-specific expression of STAT3β gene would be desirable for enhancing its antitumor potential and reducing its systemic side-effects.
Tissue-specific expression of therapeutic genes in targeted cells is a promising strategy. The macrophage-specific gene promoter can drive gene expression in macrophage cells. So far, it has been reported that macrophage-specific promoters include synthetic promoter, CD11 gene promoter, SR-A gene promoter, CD68 gene promoter and others. 28 This gene therapy strategy has been applied to therapeutic research on human diseases, such as atherosclerosis. 29 In conclusion, AdCD68STAT3β containing a STAT3β gene driven by CD68 gene promoter was used to overexpress STAT3β specifically in TAMs, and the suppressive effects on tumor progression were investigated in vitro and in vivo in our study. CD68 gene promoter directed macrophage-specific gene expression. Macrophages overexpressing STAT3β significantly inhibited the motility and invasion breast cancer cells in vitro. In tumor model animals established with 4T1 cells, overexpressed STAT3β gene in TAMs lead to suppression of breast tumor growth, angiogenesis and metastasis, probably by regulating the crosstalk between tumor cells and TAMs in vivo.
